Individual psychoeducation program for inpatients with schizophrenia
Evaluation of the Individual Early Psychoeducation Program for Schizophrenic Disorders in Inpatients: A Randomized, Multicenter Trial
This study is testing a new education program for hospitalized patients with schizophrenia to see if it helps them understand their treatment better and stay well longer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | University Hospital, Tours Academic / other |
| Locations | 11 sites (Blois and 10 other locations) |
| Trial ID | NCT05329363 on ClinicalTrials.gov |
What this trial studies
This study evaluates an individual psychoeducation program called PEPITS for inpatients diagnosed with schizophrenia and related disorders. The program is designed to be implemented by nurses during the early stages of hospitalization, aiming to enhance medication compliance and improve patient insight. By focusing on psychoeducation, the study hypothesizes that it will reduce relapse rates and enhance the overall quality of life for patients. The approach emphasizes the importance of therapeutic alliance and patient engagement in their treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 65 with a diagnosed schizophrenic disorder or related conditions who can communicate verbally.
Not a fit: Patients who do not speak French or have participated in a psycho-education group in the last two years may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve medication adherence and reduce relapse rates in patients with schizophrenia.
How similar studies have performed: Previous studies have shown that psychoeducation can improve treatment outcomes in psychiatric disorders, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18 and 65 years * Patient with a diagnosed and reported schizophrenic disorder announced : * Schizophrenia * Schizoaffective disorder * Or a diagnosed and reported Delusional Disorder * Express written consent by the participant after receiving information about the study * Be able to communicate verbally * Participant affiliated to a social security scheme Exclusion Criteria: * Pregnant or breastfeeding woman * Patient who does not speak French * Participation in a psycho-education group in the last 2 years * Patient under legal protection or guardianship
Where this trial is running
Blois and 10 other locations
- Serrvice de Psychiatrie — Blois, France (Withdrawn)
- Service de psychiatrie — Chinon, France (Recruiting)
- Service de psychiatrie — Dreux, France (Not_yet_recruiting)
- Service de psychiatrie — Fleury-les-Aubrais, France (Withdrawn)
- Service de psychiatrie — La Roche-sur-Yon, France (Recruiting)
- Service de psychiatrie — Neuilly-sur-Marne, France (Not_yet_recruiting)
- Service de psychiatrie — Rennes, France (Recruiting)
- Service de psychiatrie — Saint-Maurice, France (Not_yet_recruiting)
- Service de psychiatrie — Sainte-Gemmes-sur-Loire, France (Recruiting)
- Service de psychiatrie — Sotteville-lès-Rouen, France (Not_yet_recruiting)
- Service de psychiatrie — Tours, France (Recruiting)
Study contacts
- Study coordinator: Arnaud CHESSE
- Email: A.CHESSE@chu-tours.fr
- Phone: +33(0)2.34.37.89.68
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.